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Midpoint potentialNO synthase enzymes (NOS) support unique single-electron transitions of a bound H4B cofactor during catal-
ysis. Previous studies showed that both the pterin structure and surrounding protein residues impact H4B
redox function during catalysis. A conserved Arg residue (Arg375 in iNOS) forms hydrogen bonds with the
H4B ring. In order to understand the role of this residue in modulating the function of H4B and overall NO syn-
thesis of the enzyme, we generated and characterized three mutants R375D, R375K and R375N of the oxyge-
nase domain of inducible NOS (iNOSoxy). The mutations affected the dimer stability of iNOSoxy and its
binding afﬁnity toward substrates and H4B to varying degrees. Optical spectra of the ferric, ferrous, ferrous
dioxy, ferrous-NO, ferric-NO, and ferrous-CO forms of each mutant were similar to the wild-type. However,
mutants displayed somewhat lower heme midpoint potentials and faster ferrous heme-NO complex reactiv-
ity with O2. Unlike the wild-type protein, mutants could not oxidize NOHA to nitrite in a H2O2-driven reac-
tion. Mutation could potentially change the ferrous dioxy decay rate, H4B radical formation rate, and the
amount of the Arg hydroxylation during single turnover Arg hydroxylation reaction. All mutants were able
to form heterodimers with the iNOS G450A full-length protein and displayed lower NO synthesis activities
and uncoupled NADPH consumption. We conclude that the conserved residue Arg375 (1) regulates the
tempo and extent of the electron transfer between H4B and ferrous dioxy species and (2) controls the reac-
tivity of the heme-based oxidant formed after electron transfer from H4B during steady state NO synthesis
and H2O2-driven NOHA oxidation. Thus, Arg375 modulates the redox function of H4B and is important in con-
trolling the catalytic function of NOS enzymes.
© 2011 Elsevier Inc. All rights reserved.1. Introduction
Nitric oxide (NO), an inorganic radical, plays an important role in
physiology and pathology [1–3]. In mammals NO is largely produced
by nitric oxide synthase (NOS) enzymes from L-arginine (Arg). NOSs
are ﬂavo-heme enzymes that catalyze a stepwise oxidation of L-Arg
to form nitric oxide (NO) and L-citrulline [4–6]. The overall biosyn-
thetic reaction consumes 1.5 NADPH and 2 O2 and involves two
steps: the ﬁrst being Arg hydroxylation to form N-hydroxy-L-Arg
(NOHA) as a bound intermediate, and the second being NOHA oxida-
tion to form citrulline and NO (Scheme 1). Three mammalian NOS
isozymes have been characterized: neuronal NOS (nNOS, type I),
macrophage inducible NOS (iNOS, type II) and endothelial NOS+1 330 339 5022.
+1 216 636 0104.
tuehrd@ccf.org (D.J. Stuehr).
rights reserved.(eNOS, type III) [7–9]. Each NOS is only active as a homodimer
[10,11], with eachmonomer being comprised of a N-terminal oxygenase
domain that binds Fe-protoporphyrin IX (heme), the substrate Arg, and
the cofactor 6R-tetrahydrobiopterin (H4B) [12,13], and a C-terminal ﬂa-
voprotein domain that binds FAD, FMN, and NADPH [14–16]. A central
calmodulin (CaM) binding motif links the two domains [10,15–18]. The
heme is ligated to a cysteine thiolate and acts in conjunction with H4B
to catalyze a reductive activation of molecular oxygen in both steps of
NO synthesis [19–21]. During catalysis, NADPH-derived electrons are
transferred to FAD and FMN in the NOS ﬂavoprotein domain. CaM bind-
ing activates NO synthesis by triggering inter-domain electron transfer
between the reduced FMN and ferric heme groups in the NOS homodi-
mer (Fig. 1) [22–26]. Once ferrous heme forms, it can bind O2, obtain
an electron fromH4B, generate reactive heme dioxy species, and catalyze
substrate oxidation in each NOSoxy domain [22–24,27].
H4B was found to play novel structural and electronic roles in NOS
[12,20,28,29]. It promotes dimer assembly of iNOS heme-containing
monomers, increases Arg binding afﬁnity, modiﬁes heme midpoint
Scheme 1. Biosynthesis of NO from Arginine by NOS enzymes.
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Moreover, H4B performs a critical redox function in NOS: it reduces
the heme ferrous dioxy intermediate (FeIIO2) that is formed during
oxygen activation and becomes an enzyme-bound H4B radical
[20,21,34–40]. NOS ﬂavoprotein domain then catalyzes reduction of
the biopterin radical to H4B which remains bound in the enzyme to
be used again in the second step of NO synthesis. The one-electron
redox cycling of bound H4B in NOS enzymes is unique and differs
from other enzymes like tryptophan/phenylalanine/tyrosine hydrox-
ylases which also use H4B as a cofactor but only catalyze two-electron
oxidation of H4B to generate H2B, and need a steady supply of fresh
H4B during catalysis [27,41].
Crystal structures of nNOS, iNOS, and eNOS oxygenase domain di-
mers (i.e., NOSoxy) [12,13,15,42] reveal that H4B binds near the heme
with its 2-amino-4-hydroxy-pyrimidine ring hydrogen bonded with a
heme propionate group [43,44]. The H4B ring also makes π-stacking
and/or hydrogen-bonding interactions with several conserved resi-
dues that are provided by both subunits of the NOSoxy dimer
(Fig. 2). Point mutagenesis has been utilized to probe the roles of
these residues in modulating the functions of H4B and catalytic prop-
erties of NO synthesis [37,38,45–48]. For instance, the conserved res-
idue Trp457 in iNOS and its corresponding amino residue Trp678 in
nNOS were found to regulate delivery of both electrons required for
O2 activation (i.e., kinetics of ferric heme reduction by the NOS ﬂavo-
protein domain and reduction of the heme-dioxy intermediate by
H4B) [37,38,45]. Here we are particularly interested in a conserved
Arg residue (Arg375 in iNOS), which is situated on the substrate bind-
ing helix and forms hydrogen bonds with O4 and N5 of the H4B ring
(Fig. 2). To investigate the role of Arg375 in regulating the redox func-
tion of H4B and overall NO synthesis of the enzyme, we used pointFig. 1.Model of NOS dimer structure and electron transfer pathway. Inter-domain elec-
tron transfer occurs between FMN and the heme located on the adjacent subunit.mutagenesis to generate the R375D, R375K and R375N in iNOSoxy.
We then characterized each mutant with regard to their dimer con-
tent, H4B and substrate Arg binding, heme midpoint potential, extent
of H4B radical formation, and a range of catalytic properties. Our re-
sults indicate that conserved residue Arg375 modulates the redox
function of H4B and is important in controlling the catalytic function
of NOS enzymes.Fig. 2. Protein environment of the H4B cofactor. A, Interactions between H4B and iNOS.
Several iNOS residues and the heme cofactor form a hydrogen bonding network with
the H4B cofactor. Relevant iNOS residues are shown in green; H4B (yellow), Heme
(pink) and the substrate L-Arg (blue) are shown as sticks. Two water molecules that
mediate H-bonding interactions are shown as red spheres. The hydrogen bonding in-
teractions are shown as yellow dashes. Note the π-stacking interaction between the
Trp457 side chain and H4B. The ﬁgure was made using PyMOL (http://www.pymol.
org/) with the crystal structure of the mouse iNOSoxy dimer (PDB entry 1NOD
[12,79]). B; Hydrogen bond interactions (dashed lines) between the H4B cofactor and
iNOS. Ser112, Ile456 and Trp457 make H-bonds through the main chain carbonyl
groups; Arg375 interacts through its side chain.
Fig. 3. Spectral properties of the R375 mutants. The spectra of proteins which were pu-
riﬁed in the presence of 0.5 mM Arg and 3 μM H4B are shown in solid lines. Dashed
lines show the spectra of mutants in the presence of 10 mM Arg and 200 μM H4B
after incubation proteins with high concentration of Arg and H4B overnight at 4 °C. A
difference spectrum created by subtracting the spectrum of the ferric enzyme from
the spectrum of the enzyme ferrous-CO complex is shown in dotted line in each panel.
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2.1. Materials
All reagents and materials were obtained from Sigma, Aldrich,
Alexis, or sources described previously [37,38].
2.2. Mutagenesis
Site-directed mutagenesis of Δ65iNOSoxy domain (amino acid
66–498) was performed using the QuikChange XL Mutagenesis Kit
(Agilent Technologies-Stratagene, La Jolla, CA). Mutations were con-
ﬁrmed by DNA sequencing at the Cleveland Clinic Genomics Core Fa-
cility. Mutation bases (bold and underlined) and a silent restriction
site (Italic) were introduced to the primers:
R375K_Fw: 5′ ACT GGG TGG CGA TTG TGC CTC CCA TGT CGG GAT
CCA TCA CCC CTG TCT TCC 3′
R375K_Rev: 5′ GGA AGA CAG GGG TGA TGG ATC CCG ACA TGG
GAG GCA CAA TCG CCA CCC AGT 3′
R375N_Fw: 5′ ACT GGG TGT TCA TTG TGC CTC CCA TGT CGG GAT
CCA TCA CCC CTG TCT TCC 3′
R375N_Rev: 5′ GGA AGA CAG GGG TGA TGG ATC CCG ACA TGG
GAG GCA CAA TCG ACA CCC AGT 3′
R375D_Fw: 5′ GGA AGA CAG GGG TGA TGG ATC CCG ACA TGG GAG
GCA CAA GA ACA CCC AGT 3′
R375D_Rev: 5′ GGA AGA CAG GGG TGA TGG ATC CCG ACA TGG
GAG GCA CAA TCT TCA CCC AGT 3′
DNA isolation, restriction enzyme digestion, transformation, etc.
were carried out using standard protocols.
2.3. Protein expression and puriﬁcation
Wild type and mutants with a six-histidine tag at C terminus were
over expressed in BL21 using pCWori vector and puriﬁed as reported
previously by Ni2+-nitrilotriacetate (NTA) chromatography [46].
Concentrations of NOS proteins were determined from the 444 nm
absorbance of the ferrous-CO complex, using an extinction coefﬁcient
76 mM−1 cm−1 [49].
2.4. Dimerization assessment
Protein stock solutions were incubated overnight at 4 °C in the
presence of 1 mMH4B and 10 mM Arg. The dimer contents of the pro-
teins were estimated by chromatography on an Amersham Pharmacia
Biotech Superdex-200 HR size-exclusion column equilibrated with
40 mM EPPS buffer (pH 7.4), containing 10% glycerol, 250 mM NaCl
and 3 mM DTT. The dimer:monomer ratios were derived from mea-
suring the integrated area of the corresponding elution peaks deter-
mined at 280 nm. Molecular weights of the protein peaks were
estimated relative to protein molecular weight standards.Table 1
Soret band peak absorbance values and dimeric contents of the wild-type and mutant
enzymes. UV–visible spectra were recorded at room temperature. The dimerization
contents were estimated by gel ﬁltration chromatography at 4 °C.
WT R375K R375D R375N
FeIII (−Arg, −H4B) 418 nm 418 nm 418 nm 418 nm
FeIII (+Arg, +H4B) 395 nm 395 nm 388 nm 394 nm
FeII 411 nm 412 nm 413 nm 412 nm
Ferrous-CO 444 nm 444 nm 445 nm 444 nm
Ferrous-NO 437, 567 nm 437, 567 nm 439, 568 nm 437, 567 nm
Dimer content 100% 100% 30% 38%
Fig. 4. Potentiometric reductive titration of R375K iNOSoxy. Left Panel shows spectra recorded during titration of the ferric enzyme in the presence of H4B, Arg, and mediator dyes.
Right panel plots the measured potentials vs. the logarithmic ratio of ferric/ferrous heme.
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H2O2-dependent NOHA oxidation assays were performed as de-
scribed previously [46,50,51]. In short, enzymes were incubated at
room temperature with NOHA, DTT and different concentrations of
H4B in 96-well plates. Reactions were initiated by adding 30 mM H2O2
and stopped after 10 min by adding catalase. Griess reagent solution
was then added to enable detection of nitrite production as determined
by the absorbance change at 550 nm. Nitrite was quantitated based on
NaNO2 standard solutions.
2.6. Midpoint potential titration of the mutants
Midpoint potential measurements were performed as previously
described with somemodiﬁcations [52]. Spectroelectrochemical titra-
tions were carried out at room temperature in the presence of mixed
dye (40 μM neutral red, 20 μM benzyl viologen, and 100 μM methyl
viologen). Proteins (~15 μM), which were incubated with 10 mM
Arg and 1 mM H4B at 4 °C overnight, were added to 40 mM phos-
phate buffer (pH 7.0) including 200 μM H4B, 10 mM Arg, 0.1%
Tween and the mixture of dyes described above. Protein samples
and working electrode (Au) in the cell were made anaerobic by alter-
nating cycles of vacuation and ﬂushing with nitrogen. The anaerobic
reference electrode (AgCl(s)/Ag(s)/Cl(aq)) and auxiliary electrode
(Ag(s)/KCl(aq)) were promptly placed into the cell under N2 pres-
sure. Potential titrations were performed by gradually adding small
amount of current to the system using a Radiometer PGP201 poten-
tiostat/galvanostat. The spectra were then recorded when the poten-
tial in the system were stabilized after each addition. The midpoint
potential was determined using the absorbance changes at 400 and
645 nm, which indicate the ferric to ferrous heme transition. The
midpoint potential was calculated according to the Nernst equation
and is reported relative to the standard hydrogen electrode.
2.7. Single-turnover Arg hydroxylations
Arg hydroxylation single-turnover reactionswere carried out in a Hi-
Tech SF-61 stopped ﬂow apparatus equipped for anaerobic work and
coupled to a Hi-Tech MG-6000 diode array detector, as reported previ-
ously [20,37]. The R375 mutants were pre-incubated with Arg plus
H4B or H2B on ice overnight before performing experiments because of
their lower afﬁnity toward substrate and cofactor. An anaerobic solution
that contained dithionite-reduced enzyme were transferred into the
stopped-ﬂow instrument and rapidly mixed with air-saturated EPPS
buffer at 10 °C. Ninety-six spectral scans were obtained after eachmixing. Sequential spectral data were ﬁt to different reaction models
using the Specﬁt/32 global analysis software, Version 3.0 (Spectrum
Software Associates), which could calculate the number of different en-
zyme species, their spectra, and their concentrations versus time during
the single turnover reactions. Data from eight to ten sequential reactions
were averaged to obtain the ﬁnal traces.
2.8. EPR spectra measurement
EPR spectrawere recorded on a Bruker ESP 300 electron paramagnetic
resonance spectrometer equippedwith an ER035NMRgaussmeter and a
Hewlett–Packard 5352B microwave frequency counter. All spectra were
obtained at 150 K using a microwave power of 2 mW, microwave fre-
quency of 9.45 GHz, modulation amplitude of 5.0 G, and modulation fre-
quency of 100 kHz. 10 scans per sample were accumulated to improve
the signal to noise ratio. Spin quantitations were calculated by double in-
tegration. We observed some variations in the protein concentration
(around 25%). Thus, in order to improve the measurement, protein sam-
ples were thawed after EPR data collection and protein concentration
were calculated. Double integration values were divided by the ﬁnal pro-
tein concentration. Radical concentrations versus timewere ﬁt to an A→
B→ C kinetic model, where B is the radical, using the Origin 7.5 software
(OriginLab, Northampton, MA).
2.9. Product stoichiometry analysis for Arg hydroxylation single-turnover
reaction
NOHA production from Arg was measured using the following
method. Reaction samples collected from single turnover reactions
run in anaerobic vessels were derivatized with o-phthalaldehyde,
and then analyzed by reverse-phase HPLC with ﬂuorescence detec-
tion as described previously [20,37]. In summary, after reactions
were completed, sample solutions were ﬁltered through an Amicon
Centricon device (10,000 MW cut-off) prior to derivatization for
2 min. An aliquot was then immediately injected into a Hewlett–
Packard ODS-Hypersil column and eluted with a gradient of buffer A
(5 mM ammonium acetate, pH 6.0, 20% methanol) and buffer B
(100% methanol). Retention times and concentrations of amino
acids were calculated based on Arg and NOHA standard solutions.
2.10. Ferrous NO oxidation
Reduced protein was generated by the method described previ-
ously [53,54]. Small amount of anaerobic NO-saturated buffer were
added to the reduced protein to form ferrous NO complex. Such
Fig. 5. Spectra and kinetics of iNOSoxy FeIINO oxidation reactions. Anaerobic ferrous iNOSoxy proteins in the presence of Arg (10 mM) and H4B (400 μM) were titrated by small
amounts of anaerobic NO-saturated buffer to form the ferrous NO complex, which was then rapid-mixed in a stopped ﬂow spectrophotometer with air-saturated buffer at
10 °C. Left panels contain spectra of the beginning ferrous-NO and ending ferric heme species as calculated by global analysis of the spectral data, while right panels show the con-
centration of both species versus time after mixing. Data are representative of three experiments.
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1 Z.-Q.Wang, M. Aoyagi, E. D. Getzoff and D. J. Stuehr, unpublished data.
Table 2
Rates of heme and H4B redox transitions and product yield during Arg single turnover
reactions. Ferrous wild type and mutant iNOSoxy proteins containing substrates Arg
and H4B were rapid-mixed at 10 °C with air-saturated buffer to start the reactions. Sub-
sequent heme transitions were followed by stopped-ﬂow rapid-scanning spectroscopy.
Rates were calculated by Specﬁt global analysis of diode array spectral data. H4B radical
formation and decay were monitored by EPR. NOHA productions were calculated based
on HPLC results described in the Experimental section. Values are the means±S.D. of
three determinations.
NOS FeIIO2
formation
(s−1)
FeIIO2
decay
(s−1)
H4B radical
formation
(s−1)
H4B radical
decay (s−1)
NOHA
produced per
heme
WT 67.8±3.0 20.8±0.5 11.1a 0.7±0.5 0.55±0.06
R375K 55.9±3.3 29.7±1.1 30.2±9.8 1.6±0.5 0.30±0.10
R375N 72.4±3.2 17.9±0.5 34.8±4.6 1.2±0.6 0.25±0.08
R375D NA 0.13±0.01 8.8±1.6 0.3±0.1 0.11±0.02
a Values from ref [39].
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syringe and rapidly mixed with air saturated buffer. Sequential spec-
tral data of 96 scans were ﬁt to A→ B reaction models using the Spec-
ﬁt global analysis software.
2.11. Heterodimer studies of Arg375 mutant monomer and G450A iNOS
full length monomer
60 μM iNOS wild type or mutant was incubated with urea (5 M) for
2.5 h at 15 °C to form proteinmonomer. For the heterodimer formation,
the resulting urea-treated monomer was incubated with G450A iNOS
full length protein (ratio 7:1) at 30 °C for 1 h in 40 mM EPPS, 10% glyc-
erol, 250 mM NaCl buffer containing 1 mg/ml BSA, 1 mM H4B, 3 mM
DTT, 10 mM Arg and then further incubated at 4 °C overnight. Nitrite
productions of heterodimer were assayed as described previously in
96well plates [46]. In short, about 50–80 μl heterodimerswere incubat-
ed with cofactor FAD, FMN, and other reagents including SOD and cata-
lase in eachwell, and NADPHwas added to initiate the reaction at 37 °C.
After 1 h, excess NADPH was consumed by adding lactate dehydroge-
nase (LDH) and sodium pyruvate. Absorbance difference at 550 and
650 nm was measured after adding Griess reagent to each well. Nitrite
productions were then calculated according to a standard curve made
with nitrite solutions of known concentration.
NO synthesis of heterodimers were determined by spectrophoto-
metric oxyhemoglobin assay [38,55] using extinction coefﬁcient of
38 mM−1 cm−1 for methemoglobin minus oxyhemoglobin. All sample
solutions contained 100 μM H4B, 5 mM Arg, 0.3 mM DTT, 0.1 mg/ml
BSA, 10 U/ml SOD, 346 U/ml catalase, 1 mM oxyhemoglobin and 4 μM
FMN/FAD. Reactions were initiated by adding NADPH (100 μM ﬁnal
concentration), and the absorbance changes at 401 nm were recorded
at room temperature. NADPH oxidation was monitored at 340 nm
using an extinction coefﬁcient of 6.22 mM−1 cm−1.
Antagonist experiments were done in a similar way except that
300 nM wild type iNOSoxy monomer was included during the het-
erodimer formation of the mutants.
3. Results and discussion
3.1. Spectral property, stability, binding afﬁnity for H4B and Arg, and di-
mer content of mutants
Mutations at Arg375 in iNOSoxy changed enzyme's binding afﬁnity
toward substrate Arg and cofactor H4B signiﬁcantly. When the proteins
were puriﬁed in the absence of Arg and H4B, adding high concentration
of Arg and H4B at room temperature afterwards or incubating the en-
zyme overnight at 4 °C could not cause a complete high-spin shift in
the heme iron spin state, which is a characteristic of substrate andcofactor binding (data not shown). Mutants were also found to be less
stable compared to the wild type: two mutants R375N and R375D dis-
played a P420 peak instead of a P450 peak after the addition of CO to
their dithionite reduced forms [56]. To maximize mutants' stability
and their binding afﬁnity for substrate and cofactor, we henceforth uti-
lized mutant proteins that were puriﬁed in the presence of 1 mM Arg
and 2 μM H4B for our studies, unless noted otherwise.
All three mutants displayed the Soret absorbance peaks at 418 nm
when puriﬁed in the presence of H4B and Arg, indicating that they
contained low-spin heme iron (Fig. 3) which is also observed in the
wild type NOSoxy and other mutant like W457A iNOSoxy when puri-
ﬁed in the absence of substrate and cofactor [46,57–59]. Overnight in-
cubation of proteins at 4 °C with additional H4B and Arg induced
Soret peak maxima shift to 395 nm for R375K and R375N, and
388 nm for R375D, which indicates that Arg and H4B could bind and
stabilize the heme iron in a ﬁve-coordinate high-spin state as occurs
in the wild type NOS (Table 1, Fig. 3). After addition of the reducing
agent dithionite and CO gas to the solution, mutants generated stable
ferrous-CO complexes with maximal Soret absorbance at 444 nm
(Table 1, Fig. 3). Arg375 mutants were also able to form other heme
species including ferric/ferrous NO and ferrous dioxy which displayed
similar Soret band maxima as that of the corresponding wild type
heme species. These spectral properties demonstrate that the muta-
tion does not perturb the electronic properties of the heme signiﬁ-
cantly. This ﬁnding agrees well with the crystal structures of R375
iNOSoxy mutants which showed that there are very limited structural
changes around the heme pocket compared to the wild-type iNO-
Soxy.1 We also estimated the possible conformation changes after
the mutations and observed that Lys residue in R375K can still main-
tain the interaction with the heme, as well as forming the hydrogen
bonding with O4 of H4B without signiﬁcant rearrangements of the
protein structure. However, the side chains of Asn and Asp are too
short to make direct interactions with H4B in the absence of notice-
able structural changes (Supplementary Fig. S1).
The dimer–monomer ratio of each Arg375mutant was estimated by
gel ﬁltration chromatography [38,46,58]. After incubating the enzyme
with sufﬁcient amounts of substrate and cofactor, R375K mutant was
approximately 100% dimeric. However, only approximately 38% and
30% dimer were obtained for R375N and R375D, respectively. Such de-
creases in dimer content were also observed in R375A and Trp678 mu-
tantswhere Trp 678 is another conserved amino residue involved in the
hydrogen bonding and π stacking with H4B ring in nNOSoxy [38].3.2. Peroxide assay
We next examined whether the mutants could oxidize NOHA to ni-
trite in a H2O2-driven reaction. Measurements of the reaction end
product-nitrite were carried out photometrically using the Griess Assay
in a 96-well microplate at 37 °C as described previously [46,50,51]. For
this experiment we used mutants puriﬁed in the absence of Arg and
with the presence of H4B. Protein solutions were ﬁrst incubated with
1 mMH4B overnight at 4 °C, thenwere diluted to the desired concentra-
tion and further incubated with various concentration of NOHA (1mM,
2 mM, 10 mM) or H4B (100 μM, 500 μM, 1 mM) at 30 °C for 30 min.
H2O2 solution was added to initiate the reaction, then the reaction mix-
tures were incubated for 10 min at 30 °C.
Wild type iNOSoxy protein being as a positive control displayed
normal activity comparable to our previous results [46]. However,
none of the mutants showed activities under these experimental con-
ditions regardless of increasing the enzyme concentration from
110 nM to 1.1 μM. To test whether the lower activity was attributed
to the lower binding ability of substrate NOHA and H4B, we measured
the spectra of these mutants in the presence of 1 mM NOHA and
2 J. Santolini and D. J. Stuehr, unpublished data.
Fig. 6. Global kinetic model for NO synthesis by NOS. During steady state catalysis, the enzyme molecules engage in a productive cycle that releases free NO and in a futile cycle that
releases a higher oxide of nitrogen (nitrate). Reduction of ferric enzyme to ferrous (kr) enables the heme to bind O2 and initiates catalytic reactions. After NO is made, an immediate
product of catalysis is the ferric heme-NO complex (FeIII–NO), which can either release NO (kd) or become reduced (kr′) to generate a ferrous heme-NO complex (FeII–NO). The
ferrous heme-NO complex dissociates extremely slowly and instead regenerates the active ferric enzyme by reacting with O2 (kox). The FeIIO2 intermediate can also undergo an
uncoupled reaction that generates ferric enzyme and superoxide.
Scheme 2. Arginine hydroxylation single turnover reaction by NOS enzyme.
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the high spin state suggesting normal binding of NOHA and H4B to-
ward the enzyme under the assay conditions. However, heme iron
of R375D mainly existed in the low spin state.
In peroxide assay system, H2O2 binds directly to the NOS ferric
heme forming reactive heme-oxy species and further react with Arg
or NOHA to produce nitrite in the presence or absence of H4B [46].
Since the NOS heme does not need to acquire electrons from the re-
ductase domain or H4B [50,51,58]. This method can be used to test
the reactivity of the heme pocket of the oxygenase domain for NOS
enzymes. For R375K and R375N mutants, their lower activities com-
pared to wild type iNOSoxy may be either due to the lower afﬁnity
of the enzyme for H2O2 or the reaction generating a heme-oxy species
that is less reactive toward NOHA than wild type iNOSoxy. In the case
of R375D, low binding afﬁnity toward NOHA plus the two factors
mentioned above contribute to its lower activity.
3.3. Heme midpoint potential
The NOS ferric heme midpoint potential is important in determin-
ing the thermodynamic driving force for electron transfer between the
reductase domain ﬂavins and the ferric heme. We next measured the
heme midpoint potential for R375K and R375D. A spectro-
electrochemical reductive titration was performed for the ferric en-
zyme in the presence of Arg, H4B, and mediator dyes [52].Representative data were shown in Fig. 4. The heme midpoint poten-
tial were determined to be−294±3 mV for R375K and−283±3 mV
for R375D, which are about 30 to 40 mV more negative than the wild
type iNOSoxy when measured under similar conditions (−263 mV
[52];−253 mV2).
In NOSs, the heme iron has a proximal cysteine thiolate ligand
[12,13,42] (Fig. 2). Studies have shown that the strength of the
heme-thiolate bond determines the heme midpoint potential of the
enzyme. One conserved residue Trp409 in nNOS (Trp188 in iNOS) en-
gages in π-stacking with the heme and forms hydrogen bond to the
proximal cysteine ligand. Mutation on this residue turns out to alter
the hememidpoint potential greatly by either weakening or strength-
ening the heme-thiolate bond [60]. Interestingly, our Arg375mutation
lowers the heme midpoint potential, indicating that such mutation
could ﬁne tune the heme environment even though spatially Arg375
is far from the cysteine thiolate ligand. These effects are probably me-
diated through the direct interaction of the Arg375 side chain with the
heme propionate. The decrease in the redox potential creates unfavor-
able thermodynamic change for the electron transfer from the ﬂavins
in the reductase domain and the ferric heme. In addition, the lower
heme midpoint potential also implied the conceivable changes of the
Fig. 7. Stopped-ﬂow analysis of heme transitions and kinetics during single-turnover Arg hydroxylation catalyzed by R375K, R375N and wild type iNOSoxy. Anaerobic ferrous iNO-
Soxy proteins (4 μM) in the presence of Arg (10 mM) and H4B (400 μM) were mixed in a stopped ﬂow instrument with air-saturated buffer at 10 °C and diode array spectra were
collected. Left panels contain three heme species that were detected during each reaction as calculated by global analysis of the spectral data, while right panels show their con-
centration proﬁles versus time after mixing. Data are representative of three similar experiments.
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scribed above.
3.4. Oxidation rate of the ferrous heme-NO (FeIINO) complex (kox)
The differences in kox values between the wild type and mutants
often indicate subtle changes of the heme environment. We nextdetermined kox for the wild-type and Arg375 mutants by mixing
their ferrous heme-NO complexes with an air-saturated buffer in
the stopped-ﬂow spectrophotometer, and following their subse-
quent conversion to ferric enzyme [61–64]. The starting FeIINO com-
plex and ending ferric enzyme were observed for all proteins, and
their conversion ﬁt well to a monophasic transition (Fig. 5). The cal-
culated kox values ofWT, R375K, N and D are 3.11±0.15, 6.35±0.35,
Fig. 8. Heme transitions and kinetics of R375D iNOSoxy during Arg hydroxylation sin-
gle turnover reactions. Panel A contains spectral scans collected at 0.0089 s (…),
0.00135 s (—) and 13.35 s (– –) after mixing anaerobic ferrous proteins with air-
saturated buffer at 10 °C. Panel B contains cross section analysis of the kinetic data at
426 nm and 393 nm. Data are representative of three similar experiments.
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higher kox rates, which were about 2.1 to 2.8 times faster than that
of the wild-type iNOSoxy. In combination with the results of the
heme midpoint potential measurements, mutation at Arg375 low-
ered the heme midpoint potential and increased the oxidation rate
of the ferrous heme-NO complex. Such relationship was observed
in other mutants as well. For example, W409F, W409Y nNOSoxymu-
tants and mesoheme-nNOSoxy also displayed lower heme midpoint
potentials and high kox values relative to their wild-type enzyme
[54,60,61,65–67]. For iNOSoxy, replacing Trp188 to His increases
the heme midpoint potential by 80 mV due to the strengthened
heme-thiolate bond, since His is able to form stronger hydrogen
bonding with proximal Cys ligand, and its kox rate of W188H
was found to decrease by 40% relative to wild type iNOSoxy
correspondingly.3
The correlation between the kox rate and heme midpoint poten-
tial provides a good indication about the heme environment and the
characteristics of the heme-thiolate bond. NOS heme FeII–NO com-
plexes oxidize at much higher rates compared to any other heme pro-
tein including Hb or Mb [28,54,65,68,69]. Such difference is attributed
in part by the heme-thiolate bond, causing the NOS heme FeIINO
complex to have a lower midpoint potential. Our results on Arg375
further indicate that besides the difference between the heme proxi-
mal ligands (cysteine in NOSs versus histidine in Hb, Mb and other3 Z.-Q.Wang, and D. J. Stuehr, unpublished data.heme proteins), modiﬁcations of nearby amino residue in the heme
pocket could also modulate the heme midpoint potentials and the
kox rate of NOS enzymes.
The rate of ferrous NO oxidation (kox) is one of the key parame-
ters controlling the steady state NO synthesis in full length enzymes
[63,70] (Fig. 6). During NO synthesis, practically all generated NO
binds to the NOS ferric heme forming FeIIINO before exiting the en-
zyme. Part of the FeIIINO is reduced by the attached reductase domain
and the resulting FeIINO complex must react with O2 (kox in Fig. 6)
afterwards to return to the catalytic cycle [63,70]. Unlike other
heme-thiolate proteins [54,71], NOS enzyme posses relatively high
oxidization rate of FeIINO complex which is crucial to avoid the for-
mation of a dead-end product during catalysis. The observed faster
kox rates of Arg375 mutants possibly increase the steady-state activ-
ity of iNOS by speeding the return of enzyme molecules to the pro-
ductive cycle (Fig. 6) [62,70,72].
3.5. Kinetics of heme transitions, H4B radical formation and decay during
Arg hydroxylation
Previous studies show that H4B performs a novel redox function in
NOS: it reduces the ferrous dioxy intermediate (FeIIO2) that forms dur-
ing oxygen activation. This step is critical because it enables NOS to form
the heme-oxy species that react with Arg or NOHA (Scheme 2). Since
Arg375 forms hydrogen bond with the H4B ring, we investigated
whether mutation affects the redox function of H4B during single cata-
lytic turnover Arg hydroxylation.
First, we monitored the heme transitions that occur during a sin-
gle turnover Arg hydroxylation reaction run at 10 °C in the stopped-
ﬂow spectrophotometer. Air-saturated buffer was mixed with anaer-
obic ferrous iNOSoxy proteins that contained H4B and Arg and the
subsequent heme transitions were followed by UV–visible scanning
[20,37,73]. Figs. 7 and 8 contain representative data collected during
reactions catalyzed by wild type, R375K, R375N and R375D iNOSoxy.
In Fig. 7, the left panels show the light absorbance spectra of the three
enzyme species that were detected during each reaction, while the
right panels show the concentration of each species changed with
time during the reaction. In all mutants we could identify a beginning
ferrous species, a heme-dioxy (FeIIO2) intermediate, and an ending
ferric species. Their Soret absorbance maxima for each heme species
matched very well among wild-type and mutants. The ending ferric
species for all mutants displayed a 390–393 nm peak, which indicated
that their heme groups were predominantly in high spin state at the
end of the single turnover reactions. In Fig. 8, Panel A shows the scan-
ning traces collected at different time after mixing anaerobic ferrous
R375D proteins with air-saturated buffer at 10 °C. Panel B contains
cross section analysis of the kinetic data at 426 nm for the decay of
the heme ferrous dioxy and 393 nm for the formation of the ferric en-
zyme. These results showed that Arg375 mutations still permitted
buildup of a FeIIO2 intermediate, and did not signiﬁcantly alter its
spectral characteristics or those of the ferrous or ferric species. For-
mation and disappearance of the FeIIO2 intermediate were best de-
scribed by monophasic transitions, consistent with previous reports
[20,37,73]. The mutants showed similar FeIIO2 formation rate as of
the wild type iNOSoxy (Table 2). However, the transition of the
FeIIO2 intermediate to ferric enzyme was found to be different
among mutants: R375N and R375K mutants demonstrated similar
or faster rate, respectively, compared to wild type, but much slower
FeIIO2 decay rate was observed in the R375D mutant (Table 2). Our
previous results show that the electron transfer from H4B to ferrous
dioxy species in wild type iNOSoxy increases the ferrous dioxy
decay rate by 40 fold compared to the H2B-bound protein (H2B can-
not reduce the ferrous dioxy species). To elucidate the redox role of
H4B in Arg375 mutants, we performed the single turnover Arg hy-
droxylation reactions using H2B-bound R375D mutant as well. Three
heme species were observed, whose spectral features were identical
Fig. 9. H4B radical formation and decay during Arg hydroxylation in Arg375 mutants and wild-type iNOSoxy. Anaerobic ferrous iNOSoxy proteins were rapidly mixed with an air-
saturated solution at 10 °C to start the reaction. Reactions were aged at the various times (16 ms to 5 s), and then quenched by rapid freezing. EPR traces are shown for Arg375
mutants and wild-type iNOSoxy.
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(data not shown). However, conversion of the FeIIO2 intermediate
to ferric enzyme was 5 times slower in the H2B-bound proteins, sug-
gesting H4B is able to transfer an electron to the heme ferrous dioxyFig. 10. Calculated concentrations of the H4B radical versus time during Arg hydroxylation in
calculated by double integration of the EPR signals shown in Fig. 9 and divided by the protspecies of Arg375 mutants during Arg hydroxylation single turnover
reactions.
We next studied H4B radical formation and decay during Arg hy-
droxylation. Rapid-freeze experiments showed that a radical with gArg375 mutants and wild-type iNOSoxy. The relative concentration of H4B radical was
ein concentration.
Table 3
Catalytic activities of heterodimers formed by the Arg375 mutants or wild type iNO-
Soxy and G450A iNOS. NO synthesis and NADPH oxidation were measured at room
temperature and NO2− production measurement was performed at 30 °C as described
under “Materials and methods.” The values are the mean±S.D. of three measurements.
WT, wild type.
Heterodimer Native
WT iNOS
R375K R375N R375D WT
NO synthesis (min−1) 17.6
±0.6
8.6±0.3 1.7±0.1 51.8
±0.4
50.9
±0.2
NADPH oxidation
(min−1)
62.5
±4.0
64.2
±3.8
50.1
±4.4
80.3
±6.2
78.2
±3.1
NO2− production (μM)
(NO2−/μM G450A/min)
7.8±0.2 6.3±0.1 1.8±0.1 30.3
±0.7
NA
NO/NADPH 3.6 7.5 29.4 1.6 1.5
Antagonist Study 29% 30% 13% 100% NA
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actions (Fig. 9). The spectra and saturation properties of the mutant
radicals were either identical or similar to those of the H4B radical
formed in wild-type iNOSoxy [13,20,37,42,74]. Signal intensities
were used to calculate the amount of H4B radical per heme that was
present at each time point. The kinetic data were ﬁt to a two step pro-
cess including the radical formation and decay (Fig. 10). The relative
rates of H4B radical formation are consistent with the different fer-
rous dioxy disappearance rates we observed in the mutants, and
imply that there is faster ferrous dioxy reduction by H4B in the
R375K and R375N mutants compared to the wild type. Apparently
R375 mutations alter the tempo of electron transfer: in R375K and
R375N mutants, H4B transfers an electron faster than in the wild
type protein, while H4B transfers an electron slower in the R375D
mutant. Our kinetic data also suggest the mutations do not greatly af-
fect the stability of the H4B radical since all mutants displayed similar
H4B decay rates compared to the wild type within experimental error.
Our data analysis also shows that a normal level of H4B radical accu-
mulated in the R375Kmutant reaction (about 0.78 per heme) compared
to wild type iNOSoxy [37]. However, there was less H4B radical accumu-
lation (0.4 and 0.2 radical per heme, respectively) during the single turn-
over reactions of R375N and R375D iNOSoxy. Increasing the H4B
concentration in the reactions from 1 to 5 mM did not alter the results
in any way (data not shown), suggesting that the observed differences
were not due to incomplete H4B binding. The poor radical buildup ob-
served in these mutants might be due to their incomplete dimer forma-
tion, or possibly some unreacted H4B remaining in the enzyme.
We then studied the stoichiometry of Arg hydroxylation in the
Arg375 mutants. NOHA was the only amino acid product in all cases
and its formation depended completely on H4B (data not shown).
The R375K, R375N and R375D mutants consistently catalyzed about
0.30, 0.25 and 0.11 of Arg hydroxylation on a per heme basis during
the single turnover Arg hydroxylation reactions, respectively, which
are all less extensive than in the wild type (0.55, Table 2).
Previous studies suggest that a complete and well coupled electron
transfer between H4B and FeIIO2 occurred for wild type NOS proteins
in Arg hydroxylation single turnover reactions. Thus, one would expect
that Arg hydroxylation should generate 1 NOHA/heme. However, we
and others [20,73–75] typically observe substoichiometric NOHA for-
mation in single turnover reactions ranging from 0.2 to 0.8 NOHA
formed per heme, which implies that subsequent steps (i.e. conversion
of the iron-peroxo intermediate to iron-oxo or its reactionwith Arg) be-
come uncoupled in the wild type iNOSoxy within this setting. We re-
cently identiﬁed a heme-oxy reaction intermediate in the W188H
iNOSoxy [60], further studies should be able to shed light on this
issue. Here, the mutation at Arg375 even further decreased the product
stoichiometry compared to thewild type protein. One possibility is that
Arg375 mutations might diminish the reactivity of the heme-basedoxidant toward Arg, since this effect will only occur after H4B reduces
the FeIIO2 intermediate. Our H2O2-driven NOHA oxidation results sup-
ported this assumption since the heme-based oxidant formedwhen fer-
ric NOS reacts with H2O2 is thought to be similar or identical to the
species that hydroxylates NOHA during normal NOS catalysis [33,61].
For the R375N and D mutants, their incomplete enzyme dimerization
would also diminish the product stoichiometry.3.6. Activities of mutant heterodimers
To test whether mutation at Arg375 affect the NO synthesis activ-
ity, we made heterodimers by incubating the monomer of wild type
iNOSoxy (or mutants) and full-length G450A iNOS. The point muta-
tion Gly450 to Ala prevents itself forming homodimer, thus the re-
ductase domain from G450A is only capable of transferring electron
to the iNOSoxy which enables NO production from the oxygenase do-
main [46,76,77]. We ﬁrst converted oxygenase domains of wild type
and mutants to monomer by adding urea, then incubated such mono-
mer with full-length G450A protein in the presence of H4B and Arg to
form heterodimer. We next measured the rates of NO synthesis and
NADPH oxidation of these heterodimers in the presence of Arg and
H4B at 25 °C using the spectrophotometric oxyhemoglobin assay. Re-
sults are summarized in Table 3.
The NO synthesis activity of the heterodimer containing iNOSoxy
wild type was very close to the native wild type full length iNOS en-
zyme, which validates the experimental approach. All mutants showed
lower NO synthesis activitieswith only 35%, 17% and 7% of thewild type
for R375K, N and D, respectively. However, their concurrent rates of
NADPH oxidation were also reduced to a lesser degree. In general, NO
synthesis from Arg displays a stoichiometry of 1.5 NADPH oxidized
per NO formed for wild type full length NOSs [18,78]. This minimum
value was observed for our wild-type heterodimer iNOS at 25 °C,
while a stoichiometry of 3.5, 7.5, and 29NADPHoxidized perNO formed
were found for R375K, R375N and R375D, respectively (Table 3). This
indicates that a majority of the NADPH oxidation is uncoupled from
their NO synthesis in the Arg375 mutants.
Nitrite production of heterodimer measured by Griess assay also
showed the lower activity of mutants compared to the wild type,
which is consistent with the results from our NO measurements
(Table 3). One could argue that the lower activity might be due to the
low afﬁnity of mutant monomer toward the G450A subunit. To test
this,wemeasured the capability of eachmutantmonomer to “compete”
or “antagonize”wild type iNOSoxy monomer in forming a heterodimer
with full length G450A iNOS. First, 300 nMwild type iNOSoxymonomer
formedheterodimerwithG450A iNOS. Ifmutantmonomers could com-
petewithwild type effectively, then addition of excess ofmutantmono-
mer (~3 μM) to the protein solution should reduce the nitrite
production to a level similar to that of the heterodimer we formed by
mixing mutant monomer and G450 iNOS in the absence of wild type
iNOSoxy monomer. Our results in Table 3 clearly indicate that Arg375
mutants compete successfully and completely with wild-type iNOSoxy
monomer in forming the heterodimer, eliminating the possibility that
lower activity is associated with a lower binding afﬁnity of the mutant
monomer to full length G450A iNOS. These results are also consistent
with our previous heterodimer studies of R375A mutant [46].
The catalytic proﬁles we observed for heterodimer are consistent
with our single turnover Arg hydroxylation results. Since all the hetero-
dimers have the same reductase domain subunit, lower NO synthesis
observed in the mutants solely comes from the mutant oxygenase do-
main itself and/or the inter-domain electron transfer. Negative shift of
the hememidpoint potential of Arg375mutants disfavored the electron
transfer from reductase domain to the oxygenase domain, which can
decrease the NO synthesis activity. Also the less efﬁcient electron trans-
fer from H4B and/or reduced reactivity of heme-based oxidant further
lower the NO synthesis rate in Arg375 mutants.
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Mutation of the conserved residueArg375,whose side chainH-bonds
with heteroatoms in the ring of H4B, greatly changes iNOS properties and
catalytic behavior. The decreased binding afﬁnity toward substrate and
cofactor can be overcome by purifying the enzyme in the presence of
substrates and cofactor and later incubating the enzyme with additional
amount of substrate and cofactor. However, themaximumdimer forma-
tion obtained in the R375N and Dmutant are only 38% and 30%, respec-
tively. Such a low percentage in these two mutants partially
contributes to their lower Arg hydroxylation observed in the single
turnover reactions and decreased NO synthesis rate. Mutation at
Arg375 also perturbs the heme environment which leads to the neg-
ative shift of the heme midpoint potential, faster ferrous NO oxida-
tion rate and vanished peroxide activity in H2O2-drived NOHA
oxidation compared to the wild type protein. Although replacement
of Arg375 by Lys (K) increases the tempo of electron transfer be-
tween H4B and the ferrous dioxy species formed during O2 activa-
tion, R375K still shared similar properties like other mutants, for
instance, lower NOHA production in single turnover reactions and
lower NO synthesis activities and uncoupled NADPH oxidation. We
attribute these properties mainly to the reduced reactivity of
heme-based oxidant formed after the electron transfer from H4B.
Our results suggest that the conserved residue Arg375 modulates
the redox and structural functions of H4B, and is thereby important
in controlling the catalytic behavior of NOS enzymes.
Supplementary materials related to this article can be found on-
line at doi:10.1016/j.jinorgbio.2011.11.015.
Abbreviations
NOS nitric oxide synthase
iNOS inducible nitric oxide synthase
iNOSoxy the oxygenase domain of inducible nitric oxide synthase
Arg L-arginine
DTT dithiothreitol
NO nitric oxide
EPPS 4-(2-hydroxyethyl)-1-piperazinepropanesulfonic acid
NOHA Nω-hydroxy-L-arginine
H4B (6R)-5, 6, 7, 8-tetrahydro-L-biopterin
H2B 7,8-dihydro-L-biopterin
NED N-1-naphthylethylenediamine dihydrochloride
LDH lactate dehydrogenase
FeII ferrous heme species
FeIII ferric heme species
FeIIO2 ferrous dioxy species
FeIIINO ferric NO species
FeIINO ferrous NO species
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